Beginning today, Agilent Technologies will begin selling its gene regulation identification, which it obtained through the acquisition of a Cambridge, Massachusetts, start-up. The Boston Globe looks at the emerging field of gene regulators and their promise of new therapies.
- read this report from the Boston Globe for more